Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

First Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]

An open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinib

Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung